J&J cancer move
June 19, 2013
JOHNSON & Johnson has
announced the purchase
of privately held Aragon
Pharmaceuticals, which specialises
in the development of hormonally
based cancer treatments.
The consideration includes an
up-front cash payment of US$650
million plus additional payments
of US$350m based on the
achievement of certain milestones.
The acquisition includes Aragon’s
androgen receptor antagonist
program, including its ARN-509
compound which is currently being
evaluated in a phase II trial in
patients with castration-resistant
prostate cancer.
Dr Peter Lebowitz, who’s global
therapeutic area head, oncology,
for J&J’s Janssen Research and
Development, said ARN-509
complements the company’s
existing Zytiga medication “and
provides the potential for exciting,
novel approaches to treat prostate
cancer patients”.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 13
